Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human α1-acid glycoprotein: Evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on α1-acid glycoprotein

Pharmacogenetics

Volumn 6, Issue 5, 1996, Pages 403-415

  Hervé, Françoise ^a   Duché, Jean Claude ^a   D'Athis, Philippe ^b   Marché, Catherine ^a   Barré, Jérôme ^a   Tillement, Jean Paul ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

1 acid glycoprotein; Drug binding; Genetic variants

Indexed keywords

CHLORPROMAZINE; DIPYRIDAMOLE; DISOPYRAMIDE; GENE PRODUCT; IMIPRAMINE; LIDOCAINE; METHADONE; MIFEPRISTONE; OROSOMUCOID; PROGESTERONE; RADIOLIGAND; WARFARIN;

ARTICLE; BINDING COMPETITION; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; DRUG TRANSPORT; EQUILIBRIUM DIALYSIS; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; STOICHIOMETRY;

BINDING, COMPETITIVE; CARRIER PROTEINS; CHLORPROMAZINE; DIPYRIDAMOLE; DISOPYRAMIDE; HUMANS; LIDOCAINE; LIGANDS; METHADONE; OROSOMUCOID; PHARMACEUTICAL PREPARATIONS; PROGESTERONE; VARIATION (GENETICS);

EID: 0029821703     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199610000-00004     Document Type: Article

References (48)

1. Abramson FP. Methadone plasma protein binding: Alterations in cancer T and displacement from ailpha-1-acid glycoprotein. Clin Pharmacol Ther 1982: 32, 652-658.
2. Blain PG, Mucklow JC, Rawlins MD, Roberts DF, Routledge PA, Shand DG. Determinants of plasma alpha-1-acid glycoprotein in health. Br J Clin Pharmacol 1985: 20, 500-502.
3. Bredesen JE, Kierulf P. Relationship between alpha-1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide. Br J Clin Pharmacol 1984: 18, 779-784.
4. Chen RF. Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 1967: 242, 175-181.
5. De LEVE LD, Pfiasky KM. Clinical significance of plasma binding of basic drugs. Trends Pharmacol Sci 1981: 2, 283-284.
6. Dente L, Pizza MG, Metspalu A, Cortese R. Structure and expression of the genes coding for human alpha-1-acid glycoprotein. EMBO J 1987: 6, 2289-2296.
7. Dente L, Ruther U, Tripodi M, Wagner EF, Cortese R. Expression of human alpha-1-acid glycoprotein genes in cultured cells and in transgenic mice. Gene Devel 1988: 2, 259-266.
8. Eap CB, Baumann P. Isoelectric focusing of alpha-1-acid glycoprotein (orosomucoid) in immobilized pH gradients with 8M urea: Detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. Elertrophoresis 1988: 9, 650-654.
9. Eap CB, Cuendet C, Baumann P. Orosomucoid (alpha-1-acid glycoprotein) phenotyping by use of immobilized pH gradients with 8M urea and immunoblotting. A new variant encountered in a population study. Hum Genet 1988a: 80, 183-185.
10. Eap CB, Cuendet C, Baumann P. Selectivity in the binding of psychotropic drugs to the variants of alpha-1-acid glycoprotein. Naunyn-Schmiedeberg's Arch Pharmacol 1988b: 337, 220-224.
11. Eap CB, Cuendet C, Baumann P. Binding of amitriptyline to alpha-1 -acid glycoprotein and its variants. J Pharm Pharmacol 1988c: 40, 767-770.
12. Eap CB, Cuendet C, Baumann P. Binding of d-methadone, 1-methadone and dl-methadone to proteins in plasma of healthy volunteers: Role of the variants of alpha-1-acid glycoprotein. Clin Pharmacol Ther 1990: 47, 538-346.
13. El-Gamal S, Wollert U, Müller WE. Optical studies on the specific interaction of dipyridamole with alpha-1-acid glycoprotein (orosomucoid). J Pharm Pharmacol 1982: 34, 152-157.
14. Gex-Fabry M, Balant LP. Pharmacokinetics of drugs. Considerations on data analysis using computer methods and currently available software for personal computers. In: Balant LP, Welling PG, eds. Handbook of experimental pharmacology, volume 110. New York: Springer Verlag, 1994: 507-527.
15. Goolkasian DL, Slaughter RL, Edwards DJ, Lalka D. Displacement of lidocaine from serum alpha-1-acid glycoprotein. Binding sites to basic drugs. Eur J Clin Pharmacol 1983: 25, 413-417.
16. Halsall HB, Villalobos AP, Ivancic JS, Bencosme Al, Chung P. Monoclonal antibodies against human orosomucoid: Tools for the exploration of structure, function and interactions. In: Baumann P, Eap CB, Müller WE, Tillement JP, eds. Alpha-1-acid glycoprotein. Genetics, biochemistry, physiological functions and pharmacology. New York: Alan R Liss Inc. 1989: 67-84.
17. Hartrick CT, Dirkes WE, Coyle DE, Prithvi P, Denson DD. Influence of bupivacaine on mepivacaine protein binding. Clin Pharmacol Ther 1984: 36, 546-550.
18. Haughey DB, Steinberg I, Lee MH. Protein binding of disopyramide-displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein. J Pharm Pharmacol 1985: 37, 285-288.
19. Hervé F, Rajkowski KM, Martin MT, Dessen P, Cittanova N. Drug binding properties of rat alpha-1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxine and cholic acid. Biochem J 1984: 221, 401-406.
20. Hervé F, Rajkowski KM, Martin MT, Dessen P, Cittanova N. Drug-binding properties of rat alpha-foetoprotein. Specilicities of the phenylbutazone and warfarin-binding sites. Biochem J 1986: 239, 451-458.
21. Hervé F, Duché JC, Barré J, Millot MC, Tillement JP. pH titration curves of the desialylated human alpha-1-acid glycoprotein variants by combined isoelectrofocusing-electrophoresis: utilization in the development of a fractionation method for the protein variants by chromatography on immobilized metal affinity adsorbent. J Chromatogr 1992: 577, 43-59.
22. Hervé F, Gomas E, Duché JC, Tillement JP. Fractionation of the genetic variants of human alpha-1-acid glycoprotein in the native form by chromatography on an immobilized copper(II) affinity adsorbent. Heterogeneity of the separate variants by isoelectrofocusing and by concanavalin A affinity chromatography. J Chromatogr 1993a: 615, 47-57.
23. Hervé F, Gomas E, Duché J-C, Tillement JP. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha-1-acid glycoprotein. Br J Clin Pharmacol 1993b: 36, 241-249.
24. Hervé F, Urien S, Albengres E, Duché JC, Tillement JP. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 1994: 26, 44-58.
25. Hervé F, Millot MC, Eap CB, Duché JC, Tillement JP, A two-step Chromatographic purification of human alpha-1-acid glycoprotein. Its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent. J Chromatogr 1996: 678, 1-14.
26. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988: 40, 1-47.
27. Kushner I, Mackiewicz A. Acute phase proteins as disease markers. Disease Markers 1987: 5, 1-11.
28. Kute T, Westphal U. Steroid-protein interactions. XXXIV. Chemical modification of alpha-1-acid glycoprotein for characterization of the progesterone binding site. Biochim Biophys Acta 1976: 420, 195-213.
29. McElnay JC, D'Arcy PF. Protein binding displacement interactions and their clinical importance. Drugs 1983: 25, 495-513.
30. Müller WE, Stillbauer AE. Characterization of a common binding site for basic drugs on human alpha-1-acid glycoprotein (orosomucoid). Naunyn-Schmiedeberg's Arch Pharmacol 1983: 322, 170-173.
31. Øie S. Drug distribution and binding. J Clin Pharmacol 1986: 26, 583-586.
32. Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM. Methadone binding to orosomucoid (alpha-1-acid glycoprotein): Determinant of free fraction in plasma. Clin Pharmacol Ther 1981: 29, 211-217.
33. Routledge PA. The plasma protein binding of basic drugs. Br J Clin Pharmacol 1986: 22, 499-506.
34. Routledge PA. Clinical relevance of alpha-1-acid glycoprotein in health and disease. In: Baumann P, Eap CB, Müller WE, Tillement JP, eds. Alpha-1-acid glycoprotein. Genetics, biochemistry, physiological functions and pharmacology. New York: Alan R Liss Inc. 1989: 185-198.
35. Schmid K. Alpha-1-acid glycoprotein. In: Putnam FW, ed. The plasma proteins. Structure, function and genetic control, 2nd edition, volume 1 (4). New York, San Francisco, London: Academic Press, 1975: 183-228.
36. Schmid K, Field RA, Yoshizaki H. Constancy of alpha-1-acid glycoprotein variants of caucasian patients under conditions of severe stress. J Med Genet 1968: 5, 36-39.
37. Snedecor GW, Cochran WG. Statistical methods, 6th edition. Ames, IA, USA: The Iowa State University Press, 1957: 425-466 and 497-523.
38. Sugiyama Y, Suzuki Y, Sawada Y, Kawasaki S, Beppu T, Iga T, Hanano M. Auramine O as a fluorescent probe for the binding of basic drugs to human alpha-1-acid glycoprotein (AAG). The development of a simple fluorimetric method for the determination of AAG in serum. Biochem Pharmacol 1985: 34, 821-829.
39. Tillement JP, Houin G, Zini R, Urien S, Albengres E, Barré J, Lecomte M, D'Athis P, Sebille B. The binding of drugs to blood plasma macromolecules: Recent advances and therapeutic significance. Adv Drug Res 1984: 13, 59-94.
40. Tinguely D, Baumann P, Conti M, Jonzier-Perey M, Schöpf J. Interindividual differences in the binding of antidepressants to plasma proteins: The role of the variants of alpha-1-acid glycoprotein. Eur J Clin Pharmacol 1985: 27, 661-666.
41. Tomei L, Eap CB, Baumann P, Dente L. Use of transgenic mice for the characterization of human alpha-1-acid glycoprotein (orosomucoid) variants. Hum Genet 1989: 84, 89-91.
42. Urien S, MicroPharm, a software designed to analyse pharmacological data from kinetic, binding and tissue extraction experiments. Bull Cancer 1991: 78, 654.
43. Urien S, MicroPharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharmacol Res 1995: 12, 1225-1230.
44. Verbeeck RK, Cardinal JA, Hill AG, Midha KK. Binding of phenothiazines neuroleptics to plasma proteins. Biochem Pharmacol 1983: 32, 2565-2570.
45. Westphal U. Steroid-protein interactions. XIII. Interaction of progesterone and other steroids with alpha-1-acid glycoprotein. In: Gross F, Labhart A, Mann T, Samuels LT, Zander J, eds. Monographs on endocrinology, volume 4. New York: Springer Verlag, 1971: 375-433.
46. Wong AKL, Hsia JC. In vitro binding of propranolol and progesterone to native and desialylated human orosomucoid. Can J Biochem Cell Biol 1983: 61, 1114-1116.
47. Yoshizaki H, Hunziker K, Schmid K. The constancy of the types of alpha-1-acid glycoprotein variants in patients with uterectomy and irradiation. Clin Chim Acta 1969: 23, 147-151.
48. Yuasa I, Weidinger S, Umetsu K, Suenaga K, Ishimoto G, Eap CB, Duché JC, Baumann P. Orosomucoid system: 17 additional orosomucoid variants and proposal for a new nomenclature. Vox Sang 1993: 64, 47-55.